inclusion criteria: a. hospital setting: positive virus test for sars-cov-2 using rt-pcr, or positive point-of-care viral infection test in the presence of strong clinical suspicion of sars-cov-2 infection. b. home setting: positive virus test for sars-cov-2 using a molecular assay e.g. rt-pcr in the presence of strong clinical suspicion of sars-cov-2 infection. male or female, ≥18 years of age (hospital setting) or ≥50 years of age (home setting) at the time of consent. a. hospital setting: patients admitted to hospital due to the severity of their covid 19 disease or b. home setting: non-hospitalised patients from high-risk groups, defined as ≥65-years of age, or ≥50 years of age and with any of the following risk factors: arterial hypertension cardiovascular disease diabetes mellitus chronic lung disease chronic kidney disease (egfr <60 ml/min/1.73m2) chronic liver disease immunodeficiency due to a serious illness or medication cerebrovascular disease malignancy (except basal cell carcinoma) diagnosed in the last 5 years body mass index ≥30 who present with clinical symptoms consistent with covid-19: high temperature and/or new, continuous cough. loss or change to sense of smell and/or taste provide informed consent. a. hospital setting: hospitalised female patients must be ≥1 year post-menopausal, surgically sterile, or using an acceptable method of contraception. b. home setting: non-hospitalised female patients must be ≥1 year post-menopausal or surgically sterile.

inclusion criteria: a. hospital setting: positive virus test for sars-cov-2 using rt-pcr, or positive point-of-care viral infection test in the presence of strong clinical suspicion of sars-cov-2 infection. b. home setting: positive virus test for sars-cov-2 using a molecular assay e.g. rt-pcr in the presence of strong clinical suspicion of sars-cov-2 infection. male or female, ≥18 years of age (hospital setting) or ≥50 years of age (home setting) at the time of consent. a. hospital setting: patients admitted to hospital due to the severity of their covid 19 disease or b. home setting: non-hospitalised patients from high-risk groups, defined as ≥65-years of age, or ≥50 years of age and with any of the following risk factors: arterial hypertension cardiovascular disease diabetes mellitus chronic lung disease chronic kidney disease (egfr <60 ml/min/1.73m2) chronic liver disease immunodeficiency due to a serious illness or medication cerebrovascular disease malignancy (except basal cell carcinoma) diagnosed in the last 5 years body mass index ≥30 who present with clinical symptoms consistent with covid-19: high temperature and/or new, continuous cough. loss or change to sense of smell and/or taste provide informed consent. a. hospital setting: hospitalised female patients must be ≥1 year post-menopausal, surgically sterile, or using an acceptable method of contraception. b. home setting: non-hospitalised female patients must be ≥1 year post-menopausal or surgically sterile.

inclusion criteria: 1. a. hospital setting: positive virus test for sars-cov-2 using rt-pcr, or positive point-of-care viral infection test in the presence of strong clinical suspicion of sars-cov-2 infection. b. home setting: positive virus test for sars-cov-2 using a molecular assay e.g. rt-pcr in the presence of strong clinical suspicion of sars-cov-2 infection. 2. male or female, ≥18 years of age (hospital setting) or ≥50 years of age (home setting) at the time of consent. 3. a. hospital setting: patients admitted to hospital due to the severity of their covid 19 disease or b. home setting: non-hospitalised patients from high-risk groups, defined as ≥65-years of age, or ≥50 years of age and with any of the following risk factors: - arterial hypertension - cardiovascular disease - diabetes mellitus - chronic lung disease - chronic kidney disease (egfr <60 ml/min/1.73m2) - chronic liver disease - immunodeficiency due to a serious illness or medication - cerebrovascular disease - malignancy (except basal cell carcinoma) diagnosed in the last 5 years - body mass index ≥30 who present with clinical symptoms consistent with covid-19: - high temperature and/or - new, continuous cough. - loss or change to sense of smell and/or taste 4. provide informed consent. 5. a. hospital setting: hospitalised female patients must be ≥1 year post-menopausal, surgically sterile, or using an acceptable method of contraception. b. home setting: non-hospitalised female patients must be ≥1 year post-menopausal or surgically sterile.

inclusion criteria: 1. a. hospital setting: positive virus test for sars-cov-2 using rt-pcr, or positive point-of-care viral infection test in the presence of strong clinical suspicion of sars-cov-2 infection. b. home setting: positive virus test for sars-cov-2 using a molecular assay e.g. rt-pcr in the presence of strong clinical suspicion of sars-cov-2 infection. 2. male or female, ≥18 years of age (hospital setting) or ≥50 years of age (home setting) at the time of consent. 3. a. hospital setting: patients admitted to hospital due to the severity of their covid 19 disease or b. home setting: non-hospitalised patients from high-risk groups, defined as ≥65-years of age, or ≥50 years of age and with any of the following risk factors: - arterial hypertension - cardiovascular disease - diabetes mellitus - chronic lung disease - chronic kidney disease (egfr <60 ml/min/1.73m2) - chronic liver disease - immunodeficiency due to a serious illness or medication - cerebrovascular disease - malignancy (except basal cell carcinoma) diagnosed in the last 5 years - body mass index ≥30 who present with clinical symptoms consistent with covid-19: - high temperature and/or - new, continuous cough. - loss or change to sense of smell and/or taste 4. provide informed consent. 5. a. hospital setting: hospitalised female patients must be ≥1 year post-menopausal, surgically sterile, or using an acceptable method of contraception. b. home setting: non-hospitalised female patients must be ≥1 year post-menopausal or surgically sterile.